Glenmark Pharmaceuticals supplier risk profile Q1-2026: India-focused pharmaceutical imports, C-grade assessment.
Glenmark Pharmaceuticals received 77 shipments in Q1 2026 from 5 suppliers located in a single country. India accounted for 97.4% of shipments, with the dominant supplier being Glenmark Pharmaceuticals (India), which supplied 70 shipments. The import profile centers on HS Chapter 30 (pharmaceutical products), with HS code 300490 representing the largest share at 7.8% of total shipments.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
No sanctions watchlist name matches were detected for this importer. No suppliers in the sourcing network registered forced-labor exposure under UFLPA criteria.
5 distinct tier-1 suppliers in Q1 2026
| GLENMARK PHARMACEUTICALS | India | 70 |
| MS GLENMARK PHARMACEUTICALS | India | 2 |
| ANTHEA PHARMA PRIVATE | India | 1 |
| MANKIND PHARMA | India | 1 |
| SNOWBELL MACHINES | India | 1 |
Share of Q1 2026 inbound shipments by source country
12 tier-2 + 13 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.